Veracyte (NASDAQ:VCYT) Announces Quarterly Earnings Results

Veracyte (NASDAQ:VCYT) released its earnings results on Tuesday. The biotechnology company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.18, Briefing.com reports. The company had revenue of $139.07 million during the quarter, compared to the consensus estimate of $130.36 million. Veracyte had a return on equity of 8.05% and a net margin of 12.83%.Veracyte’s quarterly revenue was up 21.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.31 earnings per share.

Here are the key takeaways from Veracyte’s conference call:

• Veracyte delivered a strong Q1 with $139.1M total revenue (up 21% YoY), testing revenue of $135.1M (+26%), adjusted EBITDA of $42.8M (30.8% margin), and raised 2026 revenue guidance to $582M–$592M with adjusted EBITDA >26%.
• The Decipher franchise remains the primary growth engine—~28,000 tests in Q1 (+24% YoY), ~30% growth in high?risk categories, and multiple Phase III studies (GUIDANCE, ENZAMET, PredictRT) and NCCN inclusion supporting longer?term uptake.
• Afirma volumes improved to ~17,200 tests (+12% YoY) after the full transition to the V2 transcriptome, which materially reduced no?result rates (adding ~400 bps to volume) and contributed to margin improvement.
• Two upcoming launches—Prosigna LDT (OPTIMA data at ASCO; commercial mid?year) and TruMRD in muscle?invasive bladder cancer (launch by end of Q2)—are positioned as major catalysts, but commercial impact is contingent on trial readouts, guideline/reimbursement decisions and adoption.
• Strong cash generation ($35.2M from operations; $439.1M cash/short?term investments) and improved gross margins (non?GAAP 75.7%) provide flexibility to fund R&D, commercial scale-up and selective M&A aligned with the company’s oncology focus.

Veracyte Trading Down 1.4%

Shares of NASDAQ VCYT opened at $32.97 on Wednesday. The company has a market cap of $2.63 billion, a price-to-earnings ratio of 39.72 and a beta of 1.89. The stock’s 50 day simple moving average is $33.33 and its 200 day simple moving average is $38.16. Veracyte has a 12-month low of $22.61 and a 12-month high of $50.71.

Trending Headlines about Veracyte

Here are the key news stories impacting Veracyte this week:

• Positive Sentiment: Q1 results beat expectations: revenue grew ~21.5% year?over?year and Veracyte reported an EPS beat (outlets show beats ranging roughly $0.37–$0.52 vs consensus ~ $0.34). The company pointed to stronger top-line growth and improved margins. Business Wire Q1 Release
• Positive Sentiment: Raised FY-2026 revenue guidance: management updated revenue guidance to a $582.0M–$592.0M range, above consensus (~$576.5M), signaling confidence in continued demand. Guidance in Business Wire
• Positive Sentiment: Product mix and volumes driving performance: management said Decipher and Afirma test volumes exceeded expectations and helped surpass profitability targets — a key driver of near-term margin expansion. Business Wire Q1 Release
• Positive Sentiment: Near-term clinical catalyst: new Decipher bladder and prostate data will be presented at AUA 2026, which could support adoption and future revenue upside if results are favorable. Yahoo Finance AUA Preview
• Positive Sentiment: Analyst sentiment tilted constructive: Wall Street price-target averages imply material upside (~39% in one compilation), reflecting upward revisions after the quarter. Zacks Analyst Take
• Neutral Sentiment: The earnings call and full transcripts/slides are available for deeper color on margin drivers, geography/mix trends, and cadence; investors should review management’s Q&A for competitive and reimbursement details. Seeking Alpha Transcript
• Negative Sentiment: Stock weakness despite beats: shares are trading lower today on above-average volume, suggesting some investors were expecting bigger beats, clearer EPS guidance, or are booking gains after recent run?ups. MarketBeat VCYT

Analysts Set New Price Targets

A number of brokerages have issued reports on VCYT. Guggenheim dropped their target price on shares of Veracyte from $50.00 to $45.00 and set a “buy” rating for the company in a report on Monday, March 30th. Zacks Research lowered shares of Veracyte from a “strong-buy” rating to a “hold” rating in a research report on Thursday, March 12th. Morgan Stanley reduced their target price on Veracyte from $48.00 to $37.00 and set an “underweight” rating on the stock in a research report on Thursday, March 5th. Jefferies Financial Group assumed coverage on shares of Veracyte in a report on Monday, April 13th. They issued a “buy” rating and a $45.00 price target on the stock. Finally, Needham & Company LLC reissued a “buy” rating and set a $48.00 target price on shares of Veracyte in a research report on Wednesday, April 1st. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Veracyte presently has a consensus rating of “Hold” and an average price target of $43.83.

Insiders Place Their Bets

In other Veracyte news, CEO Marc Stapley sold 45,523 shares of the business’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $35.97, for a total transaction of $1,637,462.31. Following the completion of the transaction, the chief executive officer owned 357,554 shares in the company, valued at approximately $12,861,217.38. The trade was a 11.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Rebecca Chambers sold 18,341 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $36.14, for a total transaction of $662,843.74. Following the transaction, the chief financial officer directly owned 131,196 shares in the company, valued at approximately $4,741,423.44. The trade was a 12.27% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 75,782 shares of company stock worth $2,722,097 over the last 90 days. Insiders own 1.40% of the company’s stock.

Hedge Funds Weigh In On Veracyte

Several hedge funds have recently made changes to their positions in VCYT. California State Teachers Retirement System raised its position in shares of Veracyte by 0.8% during the second quarter. California State Teachers Retirement System now owns 71,095 shares of the biotechnology company’s stock worth $1,922,000 after purchasing an additional 566 shares during the period. O Shaughnessy Asset Management LLC lifted its position in shares of Veracyte by 7.9% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 7,894 shares of the biotechnology company’s stock worth $332,000 after purchasing an additional 576 shares in the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Veracyte by 159.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,104 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 679 shares during the period. Xponance LLC boosted its position in Veracyte by 12.1% during the fourth quarter. Xponance LLC now owns 6,871 shares of the biotechnology company’s stock valued at $289,000 after purchasing an additional 741 shares during the last quarter. Finally, Osaic Holdings Inc. lifted its holdings in shares of Veracyte by 21.0% during the 4th quarter. Osaic Holdings Inc. now owns 4,713 shares of the biotechnology company’s stock valued at $198,000 after buying an additional 817 shares during the last quarter.

Veracyte Company Profile

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.